Cullen Frost Bankers Inc. Has $5.07 Million Stake in Zoetis Inc. $ZTS

Cullen Frost Bankers Inc. reduced its stake in Zoetis Inc. (NYSE:ZTS) by 21.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,647 shares of the company’s stock after selling 9,223 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Zoetis were worth $5,070,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares in the last quarter. Empowered Funds LLC boosted its position in Zoetis by 6.2% during the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares during the last quarter. Intech Investment Management LLC grew its stake in shares of Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after acquiring an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after purchasing an additional 1,422 shares during the last quarter. Finally, Patton Fund Management Inc. bought a new stake in shares of Zoetis in the second quarter worth $224,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $124.04 on Monday. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $54.66 billion, a P/E ratio of 20.88, a P/E/G ratio of 2.15 and a beta of 0.97. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.40. The stock has a 50 day moving average of $123.58 and a 200-day moving average of $138.15.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter last year, the firm posted $1.58 EPS. The company’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s payout ratio is presently 35.69%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research report on Wednesday, December 3rd. Morgan Stanley set a $160.00 price objective on Zoetis in a report on Thursday, December 18th. Piper Sandler reiterated a “neutral” rating and set a $135.00 target price (down previously from $190.00) on shares of Zoetis in a report on Thursday. HSBC set a $140.00 price target on Zoetis in a research report on Wednesday, December 10th. Finally, UBS Group lowered their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Five research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, Zoetis currently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.